Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 723

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 2
Chunk 723
---
   17,359 Income tax  (2,613)  (36,272)  -   (38,885)Total tax (expense)/credit  9,656   (31,182)  -   (21,526)                 NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS  $(217,146) $(267,523) $(2,144,374) $(2,629,043)

 F-26Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE YEAR ENDED DECEMBER 31, 2024 AND 2023 

(Currency expressed in United States Dollars (“US$”)) 

(Audited)

  Provision for genomic screening services  Trading of industrial chemicals  Investment holding  Total   Year ended December 31, 2024              REVENUE $16,069  $9,494,577  $-  $9,510,646                  COST OF REVENUE  (7,316)  (8,213,809)  -   (8,221,125)                 GROSS PROFIT  8,753   1,280,768   -   1,289,521                  OTHER INCOME  122,951   1,949,522   -   2,072,473                  OPERATING EXPENSES                Sales and marketing  (125,299)  (1,861,456)  (43,929)  (2,030,684)Research and development  (47,511)  -   -   (47,511)General and administrative  (194,038)  (679,321)  (1,100,609)  (1,973,968)Provision for expected credit losses   -   (883,533)  -   (883,533)TOTAL OPERATING EXPENSES  (366,848)  (3,424,310)  (1,144,538)  (4,935,696)                 LOSS FROM OPERATIONS